Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | GART | P22102 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100673 | 0.86 | ALB (0.47) | NOD1ITGB3ITGA2BALBCTSG | |
| SCHEMBL20100671 | 0.83 | ITGB3 (0.47) | NOD1ITGB3ITGA2BALBCTSG | |
| SCHEMBL20100672 | 0.79 | NOD1 (0.40) | NOD1ITGB3ITGA2BGART | |
| SCHEMBL20126945 | 0.79 | NOD1 (0.40) | NOD1GARTALB | |
| SCHEMBL20100658 | 0.75 | NOD1 (0.52) | NOD1ITGB3ITGA2B | |
| SCHEMBL20100660 | 0.75 | NOD1 (0.52) | NOD1ITGB3ITGA2B | |
| SCHEMBL29324465 | 0.75 | NOD1 (0.57) | NOD1 | |
| SCHEMBL21955523 | 0.75 | NOD1 (0.57) | NOD1 | |
| SCHEMBL21282066 | 0.75 | NOD1 (0.57) | NOD1 | |
| SCHEMBL25715312 | 0.75 | NOD1 (0.57) | NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | NOD1 1513/4885ITGB3 4362/4885ITGA2B 4388/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | NOD1 1513/4885ITGB3 4362/4885ITGA2B 4388/4885 |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | NOD1 1513/4885ITGB3 4362/4885ITGA2B 4388/4885 |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NOD1 1373/4885ITGB3 2460/4885ITGA2B 2766/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NOD1 1373/4885ITGB3 2460/4885ITGA2B 2766/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NOD1 1373/4885ITGB3 2460/4885ITGA2B 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.